Anticoagulation for the initial treatment of venous thromboembolism in people with cancer.

CONCLUSIONS: LMWH is possibly superior to UFH in the initial treatment of VTE in people with cancer. Additional trials focusing on patient-important outcomes will further inform the questions addressed in this review. The decision for a person with cancer to start LMWH therapy should balance the benefits and harms and consider the person's values and preferences.
PMID: 29363105 [PubMed - as supplied by publisher]

Source: Cochrane Database of Systematic Reviews - January 24, 2018 Category: General Medicine Authors: Hakoum MB, Kahale LA, Tsolakian IG, Matar CF, Yosuico VE, Terrenato I, Sperati F, Barba M, Schünemann H, Akl EA Tags: Cochrane Database Syst Rev Source Type: research